1
|
Barbos V, Feciche B, Bratosin F, Tummala D, Shetty USA, Latcu S, Croitor A, Dema V, Bardan R, Cumpanas AA. Pandemic Stressors and Adaptive Responses: A Longitudinal Analysis of the Quality of Life and Psychosocial Dynamics among Urothelial Cancer Patients. J Pers Med 2023; 13:1547. [PMID: 38003862 PMCID: PMC10672688 DOI: 10.3390/jpm13111547] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2023] [Revised: 10/24/2023] [Accepted: 10/25/2023] [Indexed: 11/26/2023] Open
Abstract
The 2019 coronavirus disease (COVID-19) pandemic has had a profound influence on different sectors of society, including health. This study hypothesized a significant impact of the pandemic on the quality of life and psychosocial well-being of urothelial cancer patients, specifically anticipating a decrease in anxiety and depression scores as the pandemic progressed. The primary objectives were to assess longitudinal changes in quality of life indexes, evaluate Healthcare Anxiety and Depression Scale (HADS) score trends over three years (2020-2022), and identify any correlational patterns between the progression of the pandemic and anxiety, depression, and stress levels among this cohort. A cross-sectional analysis was conducted on Eastern Cooperative Oncology Group (ECOG) 1 and Tumor Node Metastasis (TNM) stage 1 bladder cancer patients from the Timis County Emergency Clinical Hospital in Romania. Sixty patients were evaluated each year from 2020 to 2022, utilizing a detailed selection process involving the review of both the hospital database and paper records. Key data included demographic information, medical history, and responses to the Patient Health Questionnaire (PHQ-9), Short Form (SF-36), HADS, and Generalized Anxiety Disorder (GAD-7) questionnaires. A total of 163 completed questionnaires were analyzed, providing insight into various aspects of patients' experiences during the pandemic. Notably, the mean hospitalization days ranged from 3.6 ± 2.1 days in 2020 to 4.0 ± 2.4 days in 2022 (p = 0.663). Concerns that current symptoms might be pandemic-related spiked to 63.5% in 2021, but reduced to 50.9% in 2022, with this fluctuation being significant (p = 0.026). The perception of decreased quality of or accessibility to medical care was significant over the years, with a decline to 52.7% in 2022 (p = 0.033). Quality of life assessments demonstrated an upward trend, from an average score of 55.9 ± 8.9 in 2020 to 59.3 ± 8.8 in 2022 (p = 0.049). Interestingly, anxiety levels, as indicated by the HADS survey, revealed a significant decline from a score of 7.8 in 2020 to 6.5 in 2022 (p = 0.008). On the other hand, GAD-7 scores displayed a downward trend over the years, potentially indicative of developed coping strategies (p = 0.034). This study provides a comprehensive insight into the fluctuating dynamics of psychosocial factors and quality of life among urothelial cancer patients during the pandemic years. It underscores a potential adaptive response, as evidenced by the decrease in anxiety levels and an upward trend in the quality of life scores over the period. These findings highlight the resilience and adaptability of this patient cohort amidst the challenges posed by the pandemic, potentially guiding future interventions and supports in similar health crises.
Collapse
Affiliation(s)
- Vlad Barbos
- Department XV, Discipline of Urology, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania; (V.B.); (S.L.); (A.C.); (V.D.); (R.B.); (A.A.C.)
- Doctoral School, Victor Babes University of Medicine and Pharmacy, E. Murgu Square, Nr. 2, 300041 Timisoara, Romania;
| | - Bogdan Feciche
- Department of Urology, Emergency County Hospital Oradea, Strada Gheorghe Doja 65, 410169 Oradea, Romania
| | - Felix Bratosin
- Doctoral School, Victor Babes University of Medicine and Pharmacy, E. Murgu Square, Nr. 2, 300041 Timisoara, Romania;
- Department XIII, Discipline of Infectious Diseases, Victor Babes University of Medicine and Pharmacy, E. Murgu Square, Nr. 2, 300041 Timisoara, Romania
| | - Durganjali Tummala
- Department of General Medicine, K.S. Hegde Medical Academy, Mangaluru 575018, India;
| | | | - Silviu Latcu
- Department XV, Discipline of Urology, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania; (V.B.); (S.L.); (A.C.); (V.D.); (R.B.); (A.A.C.)
| | - Alexei Croitor
- Department XV, Discipline of Urology, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania; (V.B.); (S.L.); (A.C.); (V.D.); (R.B.); (A.A.C.)
| | - Vlad Dema
- Department XV, Discipline of Urology, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania; (V.B.); (S.L.); (A.C.); (V.D.); (R.B.); (A.A.C.)
| | - Razvan Bardan
- Department XV, Discipline of Urology, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania; (V.B.); (S.L.); (A.C.); (V.D.); (R.B.); (A.A.C.)
| | - Alin Adrian Cumpanas
- Department XV, Discipline of Urology, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania; (V.B.); (S.L.); (A.C.); (V.D.); (R.B.); (A.A.C.)
| |
Collapse
|
2
|
A Retrospective Analysis of the Challenges of Urothelial Cancer Management during the COVID-19 Pandemic at a Single Academic Center in Romania. Healthcare (Basel) 2023; 11:healthcare11060812. [PMID: 36981469 PMCID: PMC10048588 DOI: 10.3390/healthcare11060812] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2023] [Revised: 03/05/2023] [Accepted: 03/07/2023] [Indexed: 03/12/2023] Open
Abstract
The COVID-19 pandemic caused major changes in the healthcare sector due to adaptations required to hospitalize and treat an impressive number of patients. This retrospective study intended to collect reliable information on urothelial cancer patients in Romania. The primary objective was to compare the pre-pandemic and pandemic periods to observe the differences that occurred in the management of patients with urothelial carcinoma. The secondary objective was to determine the risk factors for urothelial cancer progression in the study cohort correlated with the COVID-19 pandemic. All patients that were diagnosed and treated at our clinic with a diagnosis of urothelial carcinoma (transitional cell carcinoma) during 2019–2021 were included in the current study. A total of 1122 eligible unique cases were identified during the study period. The number of patients who underwent intervention in the pre-pandemic year was 421, followed by a 22.6% decrease in 2020 to 326 cases and a 13.1% increase in 2021 to 375 cases. The proportion of muscle-invasive bladder cancer (MIBC) cases was significantly higher during the pandemic years, from 30.5% MIBC cases in 2019 to 37.4% in 2020 and 39.4% in 2021, suggesting a delay in presentations during the pandemic. Stage III and IV (TNM) cases were significantly more frequent, even though approximately 40% of all patients were operated on in stage I. The number of cystectomies increased significantly, from 5.2% in 2019 and 4.3% in 2020 to 10.1% in 2021, while the number of elective surgeries decreased, although no significant difference was observed regarding the in-hospital mortality and disease progression at six months. Patients with stage III and IV at presentation had the highest likelihood of disease progression at six months (HR = 5.61). Distant invasion was the second highest risk factor (HR = 5.13), followed by MIBC type (HR = 2.49). Nevertheless, the duration of hospitalization and year of diagnosis during the COVID-19 pandemic were not significant risk factors for cancer progression at six months. It can be concluded that there was a significant delay in patient presentations in 2020, and we advocate for increased public health awareness for urothelial cancer and increased attention toward the screening and management of these patients in the following years.
Collapse
|
3
|
Anderson S, Rigney K, Hayes L, Ryan PC, Chaitanya V, Jacob PT, Abdelrahman M, Giri SK. A retrospective cohort study of bladder cancer following the COVID-19 pandemic: Are patients presenting with more aggressive disease? Ann Med Surg (Lond) 2022; 81:104430. [PMID: 35996636 PMCID: PMC9387060 DOI: 10.1016/j.amsu.2022.104430] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2022] [Revised: 08/07/2022] [Accepted: 08/12/2022] [Indexed: 11/16/2022] Open
Abstract
Background The COVID-19 pandemic has resulted in delays in the treatment of patients with urological malignancies. The management of bladder cancer (BC) in particular poses a significant challenge given the recurrent nature of the disease and the intense follow-up regime required for many cases. The aim of this study was to evaluate potential changes in the presentation and operative management of BC in our hospital following the pandemic. Materials and methods This is a retrospective cohort study. Potential BC cases were identified through the histopathology database between March 2019 and February 2021. Details were obtained on patient demographics, procedure type such as biopsy, resection or excision, grade and stage of BC. Cases were divided into two groups: period one (pre-COVID between March 2019 and February 2020) and period two (post-COVID between March 2020 and February 2021). Results A total of 207 procedures for confirmed BC were performed during the study period, 126 in period one and 81 in period two. New cases accounted for 52.4% (n = 66) and 53.1% (n = 43) of cases during periods one and two respectively. There was a higher rate of invasive disease (43.2% vs 26.2%) as well as high grade disease (47.4% vs 35.8%) in period two than in period one. Conclusion Fewer BC procedures were performed in the COVID period. The higher rate of more advanced stage and grade of disease seen in period two suggests patients are presenting later. This should be considered when allocating resources in the management of non-COVID related diseases. Further studies are needed to assess the long-term impact of COVID-19 on bladder cancer outcome. Bladder cancer is a time-sensitive condition and delays in diagnosis are associated with worse outcomes. Fewer cases of bladder cancer were seen in the first year following the COVID-19 pandemic. There was no difference in waiting times from diagnosis to treatment in the year before and after the pandemic. In the year following COVID-19 patients presented with more aggressive bladder cancer than in the year before the pandemic. The more aggressive bladder cancer seen following COVID-19 is likely due to delays in patients presenting to primary care.
Collapse
Affiliation(s)
- Steven Anderson
- Dept of Urology, University Hospital Limerick, Ireland
- Royal College of Surgeons Ireland, Ireland
- Corresponding author. 95 Forbes Quay, Lazer Lane, Dublin 2, D02H500, Ireland.
| | - Kate Rigney
- Dept of Urology, University Hospital Limerick, Ireland
| | - Leah Hayes
- Dept of Urology, University Hospital Limerick, Ireland
| | | | | | | | | | - Subhasis K. Giri
- Dept of Urology, University Hospital Limerick, Ireland
- University of Limerick, Ireland
| |
Collapse
|